Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 20Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid 3Leukemia 3Bronchiolitis Obliterans Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Recurrence 1P1b: Advanced Solid Tumors 1Malignant Solid Tumors 1Hematologic Diseases 1HER2+ Metastatic Breast Cancer 1Burkitt Lymphoma 1Brain Neoplasms 1Blast Crisis 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 20Brentuximab Vedotin 20fludarabine 16Lenalidomide 13Rituximab 12Dexamethasone 12fludarabine phosphate 10Melphalan 10Busulfan 10Mycophenolic Acid 9dacetuzumab 7Whole-Body Irradiation 7Tacrolimus 7pirtobrutinib 6Doxorubicin 6Bortezomib 6Azacitidine 6ruxolitinib 5Vincristine 5Prednisone 5Imatinib Mesylate 5ponatinib 4pomalidomide 4Mesna 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4venetoclax 3nilotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Diseases × asciminib × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡